Critical Comparison: Tectonic Therapeutic (TECX) and Its Competitors

Tectonic Therapeutic (NASDAQ:TECX) is one of 290 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Tectonic Therapeutic to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tectonic Therapeutic and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0	0	2	0	3.00
Tectonic Therapeutic Competitors	1548	4713	12321	218	2.60

Tectonic Therapeutic presently has a consensus price target of $76.00, suggesting a potential upside of 362.29%. As a group, “Biological products, except diagnostic” companies have a potential upside of 68.22%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, equities analysts clearly believe Tectonic Therapeutic is more favorable than its competitors.

Volatility and Risk

Tectonic Therapeutic has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic’s competitors have a beta of 1.05, meaning that their average share price is 5% more volatile than the S&P 500.

Insider and Institutional Ownership

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Tectonic Therapeutic and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-50.52%	-47.13%
Tectonic Therapeutic Competitors	-5,257.74%	-217.56%	-45.65%

Valuation and Earnings

This table compares Tectonic Therapeutic and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tectonic Therapeutic	N/A	$12.16 million	23.83
Tectonic Therapeutic Competitors	$550.00 million	-$36.20 million	-27.35

Tectonic Therapeutic’s competitors have higher revenue, but lower earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Tectonic Therapeutic beats its competitors on 9 of the 13 factors compared.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.